Investigation of a screening battery for immunotoxicity of pharmaceuticals using verapamil as a model compound
Citations
Altmetric:
Series / Report no.
Open Access
Type
Report
Language
en
Date
1996-12-31
Research Projects
Organizational Units
Journal Issue
Title
Investigation of a screening battery for immunotoxicity of pharmaceuticals using verapamil as a model compound
Translated Title
Onderzoek van een screenings-testbatterij voor immunotoxiciteit van geneesmiddelen gebruik makend van verapamil
Published in
Abstract
Van het geneesmiddel verapamil is geen in vivo immunotoxiciteit bekend. Deze verbinding is daarom getest als een negatieve controle ter verdere validering van een 28-daags oraal toxiciteits-onderzoek in de rat. Het protocol dat werd gehanteerd was aangevuld met zogenaamde Tier I immunotoxiciteitsparameters. Dit experiment was het laatste in een serie van vier, waarbij de bruikbaarheid van de Tier I testbatterij voor immunotoxiciteit werd onderzocht. Zoals verwacht werd geen aanwijzing voor potentiele immunotoxiciteit gevonden. In aansluiting op de gegevens van eerdere studies met geneesmiddelen kan worden geconcludeerd dat de Tier I aanpak in de rat geschikt is om potentiele immunotoxiciteit van geneesmiddelen op te sporen.<br>
Verapamil is a calcium entry blocker without known immunotoxic potential in vivo. This pharmaceutical was tested in a 28-day repeated dose oral toxicity study in rats. The protocol was extended with Tier I immunotoxicity screening parameters. The experiment was one in a series of four experiments on the suitability of this Tier I approach for immunotoxicity testing of pharmaceuticals. As expected, no evidence of immunotoxic potential was found. Together with the studies performed previously, it is concluded that the rat Tier I approach is a suitable tool to detect the immunotoxic potential of pharmaceuticals.<br>
Verapamil is a calcium entry blocker without known immunotoxic potential in vivo. This pharmaceutical was tested in a 28-day repeated dose oral toxicity study in rats. The protocol was extended with Tier I immunotoxicity screening parameters. The experiment was one in a series of four experiments on the suitability of this Tier I approach for immunotoxicity testing of pharmaceuticals. As expected, no evidence of immunotoxic potential was found. Together with the studies performed previously, it is concluded that the rat Tier I approach is a suitable tool to detect the immunotoxic potential of pharmaceuticals.<br>
Description
Publisher
Rijksinstituut voor Volksgezondheid en Milieu RIVM
Sponsors
RIVM